文献速递癫痫认知障碍与痴呆

急性症状性新生儿惊厥后早期停用抗癫痫发作药物的安全性

Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures.
PubMed 文献 · JAMA Neurol · 2021-01-01

本研究基于美国9个新生儿癫痫登记中心的303例急性症状性惊厥新生儿,比较出院时停用与维持抗癫痫发作药物(ASM)对24月龄神经发育和癫痫风险的影响。倾向性校正后,停用组WIDEA-FS评分非劣于维持组,癫痫风险无显著差异,支持多数患儿出院前停用ASM。

要点

  • 出院时停用ASM组24月龄WIDEA-FS评分非劣于维持组(校正平均差4分,90%CI -3至11)。
  • 停用与维持ASM组的癫痫风险相似(11% vs 14%,校正OR 1.5,95%CI 0.7-3.4)。
  • 结果支持多数急性症状性新生儿惊厥患儿在出院前停用ASM。

核心结论

  • 急性症状性新生儿惊厥缓解后,出院时停用ASM与维持治疗相比,24月龄功能神经发育和癫痫风险无显著差异。

研究设计与样本

  • 比较效果研究纳入303例急性症状性惊厥新生儿,来自美国9个IV级NICU中心,出生日期2015年7月至2018年3月,282例有随访数据,270例有主要结局数据。
  • 主要暴露为出院时停用ASM vs 维持ASM,结局风险经倾向性校正。

主要发现

  • 303例中194例(64%)出院时维持ASM。
  • 270例评估时平均(SD)月龄23.8(0.7)月,147例(54%)为男性;停用ASM组101例(37%),维持组169例(63%)。

临床怎么用

  • 对于急性症状性新生儿惊厥缓解后的患儿,可考虑在出院前停用ASM,而非常规维持至出院后。

局限性

  • 原始随机临床试验因入组缓慢提前终止;本研究为比较效果研究,非随机对照,需倾向性校正控制混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Antiseizure medication (ASM) treatment duration for acute symptomatic neonatal seizures is variable. A randomized clinical trial of phenobarbital compared with placebo after resolution of acute symptomatic seizures closed early owing to low enrollment. OBJECTIVE: To assess whether ASM discontinuation after resolution of acute symptomatic neonatal seizures and before hospital discharge is associated with functional neurodevelopment or risk of epilepsy at age 24 months. DESIGN, SETTING, AND PARTICIPANTS: This comparative effectiveness study included 303 neonates with acute symptomatic seizures (282 with follow-up data and 270 with the primary outcome measure) from 9 US Neonatal Seizure Registry centers, born from July 2015 to March 2018. The centers all had level IV neonatal intensive care units and comprehensive pediatric epilepsy programs. Data were analyzed from June 2020 to February 2021. EXPOSURES: The primary exposure was duration of ASM treatment dichotomized as ASM discontinued vs ASM maintained at the time of discharge from the neonatal seizure admission. To enhance causal association, each outcome risk was adjusted for propensity to receive ASM at discharge. Propensity for ASM maintenance was defined by a logistic regression model including seizure cause, gestational age, therapeutic hypothermia, worst electroencephalogram background, days of electroencephalogram seizures, and discharge examination (all P ≤ .10 in a joint model except cause, which was included for face validity). MAIN OUTCOMES AND MEASURES: Functional neurodevelopment was assessed by the Warner Initial Developmental Evaluation of Adaptive and Functional Skills (WIDEA-FS) at 24 months powered for propensity-adjusted noninferiority of early ASM discontinuation. Postneonatal epilepsy, a prespecified secondary outcome, was defined per International League Against Epilepsy criteria, determined by parent interview, and corroborated by medical records. RESULTS: Most neonates (194 of 303 [64%]) had ASM maintained at the time of hospital discharge. Among 270 children evaluated at 24 months (mean [SD], 23.8 [0.7] months; 147 [54%] were male), the WIDEA-FS score was similar for the infants whose ASMs were discontinued (101 of 270 [37%]) compared with the infants with ASMs maintained (169 of 270 [63%]) at discharge (median score, 165 [interquartile range, 150-175] vs 161 [interquartile range, 129-174]; P = .09). The propensity-adjusted average difference was 4 points (90% CI, -3 to 11 points), which met the a priori noninferiority limit of -12 points. The epilepsy risk was similar (11% vs 14%; P = .49), with a propensity-adjusted odds ratio of 1.5 (95% CI, 0.7-3.4; P = .32). CONCLUSIONS AND RELEVANCE: In this comparative effectiveness study, no difference was found in functional neurodevelopment or epilepsy at age 24 months among children whose ASM was discontinued vs maintained at hospital discharge after resolution of acute symptomatic neonatal seizures. These results support discontinuation of ASM prior to hospital discharge for most infants with acute symptomatic neonatal seizures.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Glass HC, Soul JS, Chang T, et al. Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures. JAMA Neurol. 2021. PMID: 34028496. doi:10.1001/jamaneurol.2021.1437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。